Common Contracts
4 similar Underwriting Agreement contracts by Adicet Bio, Inc., Delcath Systems, Inc., ImmunoCellular Therapeutics, Ltd., Leap Therapeutics, Inc.
27,054,667 Shares And Pre-Funded Warrants to Purchase 8,445,333 Shares Adicet Bio, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • January 24th, 2024 • Adicet Bio, Inc. • Pharmaceutical preparations • New York
As Representatives of the several Underwriters named in Schedule A attached hereto c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022
20,250,000 Shares of Common Stock Pre-Funded Warrants to Purchase 2,250,000 Shares of Common Stock Leap Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • June 18th, 2020 • Leap Therapeutics, Inc. • Pharmaceutical preparations • New York
Leap Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 20,250,000 shares (the “Firm Shares”) of Common Stock, $0.001 par value per share (the “Common Stock”), of the Company, and pre-funded warrants to purchase up to an aggregate of 2,250,000 shares of Common Stock in the form attached hereto as Exhibit A (the “Warrants”). The Company has also granted to the several Underwriters an option to purchase up to 3,375,000 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and the Warrants are herein referred to as the “Firm Securities.” The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Shares.” The Shares and the Warrants are herein referred to as the “Securities.” The shares of Common Stock issuabl
DELCATH SYSTEMS, INC. UNDERWRITING AGREEMENT [•] Shares of Common Stock [•] Pre-Funded Warrants to Purchase [•] Shares of Common StockUnderwriting Agreement • February 7th, 2020 • Delcath Systems, Inc. • Surgical & medical instruments & apparatus • New York
Delcath Systems, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom Roth Capital Partners, LLC is acting as the representative (the “Representative”), (i) an aggregate of [•] authorized but unissued shares (the “Firm Shares”) of Common Stock, par value $0.01 per share, of the Company (the “Common Stock”) and (ii) pre-funded warrants (the “Firm Pre-Funded Warrants”) to purchase up to an aggregate of [•] shares of Common Stock at an exercise price of $0.01 per share (the “Firm Pre-Funded Warrant Shares”). The Firm Shares, the Firm Pre-Funded Warrants, and the Firm Pre-Funded Warrant Shares are collectively referred to as the “Firm Securities.” The Company also proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters, (i) an aggregate of [•] authorized but unissued shares
10,000,000 Shares of Common Stock par value $0.0001 Warrants to Purchase 4,500,000 Shares of Common Stock and 1,500,000 Over-Allotment Securities ImmunoCellular Therapeutics, Ltd. UNDERWRITING AGREEMENTUnderwriting Agreement • October 19th, 2012 • ImmunoCellular Therapeutics, Ltd. • Pharmaceutical preparations • New York
